Japan resumes active recommendations of HPV vaccine after 8·5 years of suspension

Lancet Oncol. 2022 Feb;23(2):197-198. doi: 10.1016/S1470-2045(22)00002-X.

Authors

Rei Haruyama¹, Hiromi Obara², Noriko Fujita²

Affiliations

¹ Bureau of International Health Cooperation, National Center for Global Health and Medicine, Tokyo 162-8655, Japan. Electronic address: rharuyama@it.ncgm.go.jp.
² Bureau of International Health Cooperation, National Center for Global Health and Medicine, Tokyo 162-8655, Japan.

PMID: 35114115
DOI: 10.1016/S1470-2045(22)00002-X

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Female
Humans
Japan
Papillomavirus Vaccines / immunology*
Uterine Cervical Neoplasms / prevention & control*
Vaccination*
Young Adult

Substances

Papillomavirus Vaccines